Naveed Masani, MD, FASN
Paula Dutka, MSN, RN, CNN
Blood loss and iron sequestration are the leading causes of anemia in patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). 1,2 It is estimated that 5–7 mg of iron are lost during every hemodialysis treatment.3 To maintain iron homeostasis and prevent anemia, these patients require iron replacement therapy.
Current management often focuses on acute iron replacement, which can overload the body with iron and does not provide true iron maintenance. 1 This reactive treatment approach often triggers physiological processes in the body that block iron bioavailability by sequestrating it in the liver.1,3 Patients may benefit from a novel therapy that can maintain iron levels, bypass liver sequestration, and is well tolerated.
Attendees will learn about:
- Challenges of acute iron replacement therapy
- A novel iron replacement therapy with a physiologic approach to maintaining hemoglobin in adult patients with HDD-CKD
- Rostoker G, Vaziri ND, Fishbane S. Drugs. 2016;76(7):741-757.
- Fishbane SN, Singh AK, Cournoyer SH, et al. Nephrol Dial Transplant. 2015;30(12):2019-2026.
- Gupta A, Lin V, Guss C, Pratt R, Ikizler A, Besarab A. Kidney Int. 2015;88(5):1187-1194.